{"id":"W3097213049","doi":"10.1182/blood-2020-136163","title":"Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; Vancouver General Hospital; Alberta Hospital Edmonton; University of British Columbia; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network; University of Toronto; BC Cancer Agency; Alberta Health Services","funders":"","keywords":"Discontinuation; Imatinib; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Imatinib mesylate; Dasatinib; Internal medicine; Oncology; Drug holiday; Immunology; Cancer; Receptor; Human immunodeficiency virus (HIV)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003667386,0.000250414,0.0007727204,0.0002442556,0.0004596883,0.0005926893,0.0006327227,0.000489437,0.001231288],"category_scores_gemma":[0.005686034,0.00008620411,0.0009812593,0.0005242532,0.0004035754,0.0002743707,0.0003668838,0.0008302559,0.00006887175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006293295,"about_ca_system_score_gemma":0.01474274,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.18456,"about_ca_topic_score_gemma":0.3991688,"domain_scores_codex":[0.9986274,0.0005285968,0.00008001622,0.0001395932,0.0003663058,0.0002580739],"domain_scores_gemma":[0.9972887,0.0008066194,0.0008987588,0.0001031843,0.0003027304,0.000600012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3935634,0.001516136,0.3909322,0.002304932,0.003874941,0.0002692358,0.0005548969,0.01537946,0.005274679,0.002793136,0.007393413,0.1761436],"study_design_scores_gemma":[0.03976597,0.022745,0.9037873,0.0006751098,0.00438046,0.0002689224,0.0001951021,0.01054177,0.001661846,0.001326942,0.01454349,0.0001081504],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798108,0.01007038,0.0005898075,0.001423498,0.00005271053,0.0005609651,0.002192147,0.00002066155,0.005279042],"genre_scores_gemma":[0.9972873,0.0007078582,0.0004336049,0.0002293099,0.00002998445,0.0001250929,0.0009071188,0.000003050313,0.0002768082],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.18456,"threshold_uncertainty_score":0.3669716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01666384868017202,"score_gpt":0.2648742075237999,"score_spread":0.2482103588436279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}